Jiachen Wen

Jiachen Wen

Auto-generated profile, based on publicly available information

Jiachen Wen

Shenyang Pharmaceutical University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JWJiachen Wen
Jiachen Wen
SWSiyuan Wang
Siyuan Wang
RGRongxian Guo
Rongxian Guo
DLDan Liu
Dan Liu

17 April 2024 in Microbiological Research
Verified
Journal Article
Closed access
RGRongxian Guo
Rongxian Guo
XFXin Fang
Xin Fang
KSKe Shang
Ke Shang
JWJiachen Wen
Jiachen Wen
KDKe Ding
Ke Ding

31 December 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BLBo Li
Bo Li
YCYibing Chen
Yibing Chen
SWSiyuan Wang
Siyuan Wang
BJBo Jin
Bo Jin
JYJinyu Yang
Jinyu Yang
DLDan Liu
Dan Liu

1 January 2026 in Journal of Dairy Science
Verified
Journal Article
Open access
RPRuixue Pan
Ruixue Pan
YDYuexia Ding
Yuexia Ding
JPJinju Peng
Jinju Peng
YLYuner Long
Yuner Long
YZYining Zhao
Yining Zhao
YMYi Ma
Yi Ma
The emergence of methicillin-resistant Staphylococcus aureus (MRSA) and its robust biofilm-forming capability pose severe threats to public health, livestock production, and food safety, and underscores the urgent need for novel antibacterial and anti-biofilm agents. In this study, we identified and characterized a novel bacteriocin, PFB252, derived from Bacillus velezensis through a multistep purification process involving acid precipitation, TA-GF75 gel column chromatography, Tiderose Q HP anion-exchange chromatography (TRUKING, Changsha, China), and reversed-phase HPLC. PFB252 exhibited remarkable thermal stability, pH tolerance, and resistance to enzymatic degradation, and demonstrated potent antibacterial activity against MRSA. At subinhibitory concentrations (1/32× minimum inhibitory concentration [MIC] and 1/16× MIC), PFB252 significantly disrupted biofilm formation and impaired the metabolic viability of embedded bacteria, and it drastically reduced extracellular polysaccharide, the key component of the biofilm matrix. Transcriptional analysis further revealed that PFB252 at subinhibitory concentrations downregulated critical biofilm-associated genes. PFB252 exhibited strong antimicrobial efficacy in dairy applications and could reduce MRSA counts in milk from 103 to <10 cfu/mL within 4 d at MIC and maintain suppression in cheese below 102 cfu/g over 7 d. These properties highlight PFB252's potential as a natural biopreservative for combating MRSA in food systems and offer a promising solution for food safety applications.

1 January 2020 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JWJiachen Wen
Jiachen Wen
KTKelly A. Teske
Kelly A. Teske
M. Kyle HaddenM. Kyle Hadden
M. Kyle Hadden

24 January 2024
Verified
Book Chapter
Open access
PDF file
JWJiachen Wen
Jiachen Wen
SLShenglin Luan
Shenglin Luan
DLDan Liu
Dan Liu
The Colony-Stimulating Factor 1 (CSF-1) and its receptor (CSF1R) constitute an important axis that regulates the phenotype of most tissue-resident macrophages. Endogenous cytokine ligation and oncogenic mutations of CSF1R trigger the activation of several downstream pro-survival kinase cascades, thereby enhancing tumor cell proliferation and disease progression. Tumor-associate macrophages (TAMs) harboring activated CSF1R release tumorigenic cytokines, thus further deconditioning tumor immune microenvironment to a pro-tumoral phenotype. With the recent success of pexidartinib for the treatment of tenosynovial giant cell tumor, CSF1R pathway blockage has emerged as a promising TAM-targeting approach in certain types of cancers. More interventions to CSF1R, including monotherapy and combinatorial therapy, have advanced to clinical trials for a broader spectrum of cancers, highlighting such strategy to benefit cancer immunotherapy.